Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

September 15, 2006 (Vol. 26, No. 16)

Company Update: ApoLife Touts Yeast-Based Expression System

Company Cites Platform's Advantages from Discovery through Commercial Manufacturing

  • All currently marketed therapeutic Mabs are produced in mammalian cell cultures, a process that is prohibitively expensive for large-scale production. ApoLife (www.apolife.com) has perfected an alternative system that uses baker’s yeast (Saccharomyces cerevisiae) to make low-cost, high-volume recombinant proteins and functional human antibodies, according to the company. Pharmaceutical ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.